Molecular Screening for Cancer Treatment Optimization

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

2150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-28

Study Completion Date

2020-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival compared to the previous treatment line.

The secondary objectives are to investigate clinical practical feasibility of such technics, to potentially improve the overall survival of patients and to describe molecular portrait of Phase 1 candidates.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer

NCT01919749

Metastatic Breast Cancer

COMPLETED NA

Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients

NCT02626039

Metastatic Breast Cancer

COMPLETED

Molecular Profiling Protocol (SCRI-CA-001)

NCT00530192

Refractory Cancer

COMPLETED EARLY_PHASE1

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

NCT02105168

Melanoma Non Small Cell Lung Cancer Small Cell Lung Cancer

UNKNOWN NA

Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

NCT02628379

Neoplasms, Unknown Primary CUP Metastatic Disease +3 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Solid Tumors (Any Localization)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with non curable metastatic cancer

Group Type EXPERIMENTAL

Tumoral biopsy

Intervention Type PROCEDURE

Every enrolled patient undergoes tumoral biopsy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tumoral biopsy

Every enrolled patient undergoes tumoral biopsy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Solid tumors ; Stade IV ; Local relapse or metastatic ; Uncurable
* Age \> 6 months
* PS 0/1 or Lansky play scale \>= 70%
* Minimum one treatment line, no limit in the prior number of treatment line
* Evaluable or measurable disease

Exclusion Criteria

* Life expectancy \< 3 months
* Carcinomatous meningitis
* Symptomatic or progressive radiologic brain metastasis for non-CNS tumors
* Polynuclear neutrophil \< 1 x 10\^9/L
* Platelets \< 100 x 10\^9/L
* Hemoglobin \< 90 g/L
* ALT/AST \> 2.5 N
* bilirubin \> 1.5 N
* Creatinine \>1.5 N
* Calcemia \> ULN
* Phosphate \> ULN
* Coagulation anomaly non-indicated for biopsy

Minimum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No